Danaher Corporation $DHR Shares Sold by Mountain Pacific Investment Advisers LLC

Mountain Pacific Investment Advisers LLC lowered its stake in shares of Danaher Corporation (NYSE:DHR) by 36.1% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 130,269 shares of the conglomerate’s stock after selling 73,674 shares during the quarter. Danaher comprises 4.0% of Mountain Pacific Investment Advisers LLC’s portfolio, making the stock its 4th largest holding. Mountain Pacific Investment Advisers LLC’s holdings in Danaher were worth $25,827,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of DHR. CNB Bank raised its holdings in Danaher by 10.1% in the 3rd quarter. CNB Bank now owns 4,671 shares of the conglomerate’s stock worth $926,000 after acquiring an additional 428 shares during the period. Osborne Partners Capital Management LLC grew its position in shares of Danaher by 2.8% in the third quarter. Osborne Partners Capital Management LLC now owns 98,234 shares of the conglomerate’s stock valued at $19,476,000 after purchasing an additional 2,681 shares during the last quarter. Rakuten Investment Management Inc. acquired a new stake in shares of Danaher in the third quarter valued at about $862,000. Cornerstone Wealth Group LLC increased its stake in shares of Danaher by 3.6% in the third quarter. Cornerstone Wealth Group LLC now owns 20,718 shares of the conglomerate’s stock worth $4,107,000 after purchasing an additional 728 shares during the period. Finally, Brandywine Oak Private Wealth LLC lifted its position in shares of Danaher by 7.1% during the 3rd quarter. Brandywine Oak Private Wealth LLC now owns 1,379 shares of the conglomerate’s stock worth $273,000 after purchasing an additional 92 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Danaher

In other news, SVP Georgeann Couchara sold 5,174 shares of the company’s stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $210.42, for a total value of $1,088,713.08. Following the sale, the senior vice president owned 2,625 shares of the company’s stock, valued at approximately $552,352.50. This represents a 66.34% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Brian W. Ellis sold 21,776 shares of Danaher stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $219.23, for a total transaction of $4,773,952.48. Following the transaction, the senior vice president directly owned 14,553 shares of the company’s stock, valued at $3,190,454.19. This represents a 59.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 30,248 shares of company stock valued at $6,609,663. 11.10% of the stock is owned by insiders.

Analyst Ratings Changes

DHR has been the topic of a number of research analyst reports. KeyCorp reaffirmed an “overweight” rating on shares of Danaher in a report on Thursday, December 18th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Danaher in a research report on Monday, December 29th. Wells Fargo & Company upped their target price on shares of Danaher from $230.00 to $240.00 and gave the company an “equal weight” rating in a research note on Monday, December 15th. HSBC raised their price target on shares of Danaher from $255.00 to $270.00 and gave the stock a “buy” rating in a research report on Monday, December 1st. Finally, The Goldman Sachs Group boosted their price objective on shares of Danaher from $265.00 to $270.00 and gave the stock a “buy” rating in a report on Tuesday. Twenty equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Danaher presently has a consensus rating of “Moderate Buy” and a consensus price target of $252.09.

Danaher Trading Up 3.2%

DHR stock opened at $241.90 on Thursday. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $258.23. The company has a current ratio of 1.52, a quick ratio of 1.10 and a debt-to-equity ratio of 0.33. The business’s 50 day moving average is $229.62 and its 200-day moving average is $212.65. The firm has a market cap of $170.86 billion, a P/E ratio of 49.88, a P/E/G ratio of 4.17 and a beta of 0.89.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Monday, October 20th. The conglomerate reported $1.89 EPS for the quarter, beating the consensus estimate of $1.72 by $0.17. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The business had revenue of $6.05 billion for the quarter, compared to analyst estimates of $6 billion. During the same quarter in the previous year, the firm earned $1.71 EPS. Danaher’s quarterly revenue was up 4.4% on a year-over-year basis. Equities analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Friday, December 26th will be paid a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 0.5%. The ex-dividend date is Friday, December 26th. Danaher’s payout ratio is currently 26.39%.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.